Melflufen Combination Approved for Heavily Pretreated Multiple Myeloma

On March 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (melflufen) in combination with dexamethasone for the treatment of relapsed/refractory (RR) multiple myeloma (MM). Melflufen, sold commercially as PEPAXTO, is the first peptide-drug conjugate approved for the treatment of MM. The newly approved therapeutic combination has been designated for … Continue reading Melflufen Combination Approved for Heavily Pretreated Multiple Myeloma